(Q46003331)

18 December 2017

title

The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury. (English)

1 reference

18 December 2017

1 reference

4

1 reference

18 December 2017

author name string

Julia M Huber

1

1 reference

18 December 2017

Andrea Tagwerker

2

1 reference

18 December 2017

Dorothea Heininger

3

1 reference

18 December 2017

Alexander R Rosenkranz

5

1 reference

18 December 2017

Kathrin Eller

6

1 reference

18 December 2017

publication date

20 May 2009

1 reference

18 December 2017

American Journal of Physiology - Renal Physiology

published in

1 reference

18 December 2017

volume

297

1 reference

18 December 2017

issue

2

1 reference

18 December 2017

page(s)

F451-60

1 reference

18 December 2017

Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Proteasome inhibition suppresses essential immune functions of human CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Up-regulation of cell cycle regulatory genes after renal ischemia/reperfusion: differential expression of p16(INK4a), p21(WAF1/CIP1) and p27(Kip1) cyclin-dependent kinase inhibitor genes depending on reperfusion time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Proteasome inhibition: a new anti-inflammatory strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

The subunit structure and dynamics of the 20S proteasome in chicken skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

p21 and mTERT are novel markers for determining different ischemic time periods in renal ischemia-reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Role of alpha/beta and gamma/delta T cells in renal ischemia-reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

P53 mediates the apoptotic response to GTP depletion after renal ischemia-reperfusion: protective role of a p53 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Role of apoptosis in hypoxic/ischemic damage in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Effects of initial ischemia/reperfusion injury on the transplanted kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Proteasome inhibitor, bortezomib, for myeloma and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Strategies for therapeutic targeting of the p53 pathway in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

Renal Failure in Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.90576.2008

10.1152/AJPRENAL.90576.2008

21 January 2018

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017